In the last trading session, 1.36 million shares of the Inozyme Pharma Inc (NASDAQ:INZY) were traded, and its beta was 1.36. Most recently the company’s share price was $1.36, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $87.37M. INZY currently trades at a discount to its 52-week high of $7.80, offering almost -473.53% off that amount. The share price’s 52-week low was $1.32, which indicates that the current value has risen by an impressive 2.94% since then. We note from Inozyme Pharma Inc’s average daily trading volume that its 10-day average is 1.12 million shares, with the 3-month average coming to 635.05K.
Inozyme Pharma Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.11. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended INZY as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Inozyme Pharma Inc is expected to report earnings per share of -0.37 for the current quarter.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.0830 on recent trading dayincreased the stock’s daily price by 34.71%. The company’s shares are currently down -50.90% year-to-date, but still down -31.83% over the last five days. On the other hand, Inozyme Pharma Inc (NASDAQ:INZY) is -54.97% down in the 30-day period. We can see from the shorts that 3.7 million shares have been sold at a short interest cover period of 4.69 day(s).
The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 91.5% from its current value. Analyst projections state that INZY is forecast to be at a low of $16 and a high of $16.
Inozyme Pharma Inc (INZY) estimates and forecasts
Inozyme Pharma Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -74.44 percent over the past six months and at a -16.06% annual growth rate that is well below the industry average of 16.50%.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.73%.
INZY Dividends
Inozyme Pharma Inc’s next quarterly earnings report is expected to be released in February.
Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.51% of Inozyme Pharma Inc shares, and 98.58% of them are in the hands of institutional investors. The stock currently has a share float of 99.08%. Inozyme Pharma Inc stock is held by 126.0 institutions, with ADAGE CAPITAL PARTNERS GP, L.L.C. being the largest institutional investor. By 2024-06-30, it held 9.2742% of the shares, which is about 5.73 million shares worth $25.55 million.
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, with 7.2765% or 4.49 million shares worth $20.05 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Fidelity Select Portfolios – Biotechnology were the top two Mutual Funds as of Sep 30, 2024 . The former held 4.13 shares worth $5.62 million, making up 6.44% of all outstanding shares. On the other hand, Fidelity Select Portfolios – Biotechnology held roughly 1.9 shares worth around $2.59 million, which represents about 2.96% of the total shares outstanding.
